EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Biomarkers associated with clinical response to cystic fibrosis pulmonary exacerbation treatment and adjuvant prednisone therapy

Bradley S Quon, Jasleen K Matta, Michelle Shaw, Hartmut Grasemann, Felix Ratjen, Valerie Waters

Journal of Cystic Fibrosis · 2025

DOI: 10.1016/j.jcf.2025.08.018 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Bradley S Quon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, Department of Medicine, St Paul's Hospital, University of British Columbia, Vancouver, Canada. Electronic address: …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Prednisone, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Foundation, Cystic Fibrosis Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cystic fibrosis (CF) pulmonary exacerbations are characterized by increased inflammation. The objectives of this study were to identify inflammatory biomarkers associated with 1) early clinical response to IV antibiotics (by day 7); and 2) response to the delayed use of prednisone (from day 7 to 14). METHODS: This was a secondary analysis of a clinical trial evaluating the adjunctive use of prednisone in pwCF. We studied blood and sputum inflammatory markers at Day 0 that were associated with early response to IV antibiotics at Day 7 (early responder analysis). In non-responders to IV antibiotics alone, we examined biomarkers at Day 7 that were associated with response to oral prednisone at Day 14. Clinical outcomes included: 1) absolute change in ppFEV1; 2) absolute change in chronic respiratory infection symptom score (CRISS); and 3) composite outcome of absolute improvement in ppFEV1 of ≥ 8 % and CRISS score decrease by ≥ 11 (early responder analysis only). RESULTS: Higher Day 0 sputum IFN-γ and lower blood calprotectin were associated with improved Day 7 lung function response; lower Day 0 sputum IL-8 and blood eotaxin were associated with improved symptom scores. In non-responders at Day 7, higher blood eotaxin was associated with better lung function response and higher blood CRP was associated with worse symptom score response at Day 14 in those treated with prednisone versus placebo. CONCLUSION: Sputum and blood inflammatory markers are associated with early response to IV antibiotics and change with prednisone treatment during PEx.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisPrednisoneAnti-Bacterial AgentsHumansBiomarkersFemaleMaleSputumAdultDisease ProgressionRespiratory Function TestsTreatment OutcomeAdolescentAnti-Inflammatory Agents

Stichwörter der Autor:innen

Anti-inflammatoryAntibioticsBiomarkersClinical trialCystic fibrosisCytokinesInflammation

Substanzen

PrednisoneBiomarkersAnti-Bacterial AgentsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Division of Respiratory Medicine, Department of Medicine, St Paul's Hospital, University of British Columbia, Vancouver, Canada. Electronic address: Bradley.Quon@hli.ubc.ca.
  • Division of Respiratory Medicine, Department of Medicine, St Paul's Hospital, University of British Columbia, Vancouver, Canada. Electronic address: Jasleen.Kaur@hli.ubc.ca.
  • Translational Medicine, Hospital for Sick Children, University of Toronto, Toronto, Canada; Division of Respiratory Medicine, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada.…
  • Translational Medicine, Hospital for Sick Children, University of Toronto, Toronto, Canada; Division of Infectious Diseases, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada.…

Förderung

  • Cystic Fibrosis Foundation
  • Cystic Fibrosis Canada

Zitieren

APA

Quon, B. S., Matta, J. K., Shaw, M., Grasemann, H., Ratjen, F., & Waters, V. (2025). Biomarkers associated with clinical response to cystic fibrosis pulmonary exacerbation treatment and adjuvant prednisone therapy. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.08.018

Vancouver

Quon BS, Matta JK, Shaw M, Grasemann H, Ratjen F, Waters V. Biomarkers associated with clinical response to cystic fibrosis pulmonary exacerbation treatment and adjuvant prednisone therapy. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.08.018

BibTeX
@article{Quon2025,
  author = {Quon, Bradley S and Matta, Jasleen K and Shaw, Michelle and Grasemann, Hartmut and Ratjen, Felix and Waters, Valerie},
  title = {Biomarkers associated with clinical response to cystic fibrosis pulmonary exacerbation treatment and adjuvant prednisone therapy},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  doi = {10.1016/j.jcf.2025.08.018}
}
Kostenlos starten →